By Alan Zibel,Christina Rogers and AnnaMaria Andriotis
Borrowers who took out auto loans over the past year are missing payments at the highest level since the recession, fueling concerns among regulators, analysts and some in the car industry that practices that helped boost 2014 light-vehicle sales to a near-decade high could backfire.
By Jennifer Booton, MarketWatch
Toyota, Volkswagen, Mercedes-Benz offer a peek at the future
LAS VEGAS (MarketWatch)--Car makers and connected-car apps have flooded the Consumer Electronics Show this year, betting on a future of driverless fleets and alternative fuels.
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic Results suggest potential for I.V. CR845 to be first Schedule V or non-scheduled peripheral opioid for acute pain Conference Call/Webcast at 9:00 a.m. ET today
SHELTON, Conn., Oct.
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration Establishes dosing range and regimen for Phase 2 trial design SHELTON, Conn., Dec.
I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis Effective itch reduction seen in subgroup of patients with uremic pruritus Phase 2 trial in dialysis patients with uremic pruritus underway
SHELTON, Conn., Dec.
Reported positive top-line data from human abuse liability trial for I.V. CR845 Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015 Conference call today at 4:30 p.m. ET
SHELTON, Conn., Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.